Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 3/20 | 0.50 |
| ▸ | AOC1 | P19801 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553234 | 0.73 | AOC1 (0.42) | HRH3CYP2D6AOC1CYP3A4IDO1 | |
| Diphenylacetylene SCHEMBL29188592 | 0.69 | APP (1.00) | CYP2D6GRM5APPCYP3A4MAPT | |
| Diphenylacetylene SCHEMBL960609 | 0.69 | APP (1.00) | CYP2D6GRM5APPCYP3A4MAPT | |
| Diphenylacetylene SCHEMBL68254 | 0.69 | APP (1.00) | CYP2D6GRM5APPCYP3A4MAPT | |
| SCHEMBL5820056 | 0.68 | APP (0.55) | CYP2D6GRM5APPCYP3A4MAPT | |
| SCHEMBL4860070 | 0.67 | GRM5 (1.00) | GRM5APPMAPT | |
| Diphenylacetylene SCHEMBL23754282 | 0.67 | APP (0.92) | CYP2D6GRM5APPCYP3A4MAPT | |
| Diphenylacetylene SCHEMBL31243352 | 0.67 | APP (0.92) | CYP2D6GRM5APPCYP3A4MAPT | |
| Diphenylacetylene SCHEMBL9273707 | 0.67 | APP (0.92) | CYP2D6GRM5APPCYP3A4MAPT | |
| Diphenylacetylene SCHEMBL5576302 | 0.67 | APP (0.92) | CYP2D6GRM5APPCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045463-B2 | Phenyl ethynyl derivatives as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2015-06-02 | — | — | US | disclosed |
| EP-2462136-A1 | PHENYL ETHYNYL DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | Janssen R&D Ireland (IE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120136027-A1 | Phenyl Ethynyl Derivatives As Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2012-05-31 | — | — | US | disclosed |
| WO-2011015657-A1 | PHENYL ETHYNYL DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136027-A1 | Phenyl Ethynyl Derivatives As Hepatitis C Virus Inhibitors | HAVCR2, ZC3HAV1, EIF2AK2 | HRH3 1376/4885CYP2D6 148/4885GRM5 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.